论文部分内容阅读
目的 :探讨痰热清注射液联合思力华对慢性阻塞性肺疾病患者肺功能的改善作用。方法 :将82例患者随机分为对照组39例和观察组43例。对照组在常规治疗基础上给予雾化吸入噻托溴铵粉吸入剂,观察组在对照组基础上静脉滴注痰热清注射液,治疗14天后统计疗效、转化生长因子-β1(TGF-β1)阳性率、肺功能和血气分析指标,记录不良反应情况。结果 :观察组总有效率为86.1%,对照组为71.8%,2组疗效比较,差异有统计学意义(Z=2.53,P<0.05)。治疗后,2组患者的肺功能指标均有明显改善(P<0.05)。观察组的FEV1%、FEV1/FVC(%)改善优于对照组(P<0.05)。治疗后,2组患者血气分析指标Pa O2上升,Pa CO2下降,TGF-β1的阳性率降低(P<0.05);观察组与对照组比较,改善更显著(P<0.05)。结论:痰热清注射液联合思力华治疗慢性阻塞性肺疾病患者疗效显著,可改善肺功能和呼吸情况,降低TGF-β1阳性率,值得临床推广应用。
Objective: To investigate the effect of Tanreqing injection combined with SiLihua on pulmonary function in patients with chronic obstructive pulmonary disease. Methods: 82 patients were randomly divided into control group 39 cases and observation group 43 cases. The control group received inhalation of tiotropium bromide inhalation on the basis of routine treatment. The observation group was treated with intravenous infusion of Tanreqing Injection on the basis of the control group. After 14 days of treatment, the effect of TGF-β1 (TGF-β1 ) Positive rate, lung function and blood gas analysis indicators, record adverse reactions. Results: The total effective rate was 86.1% in the observation group and 71.8% in the control group. There was significant difference between the two groups (Z = 2.53, P <0.05). After treatment, pulmonary function indexes of two groups were significantly improved (P <0.05). The improvement of FEV1% and FEV1 / FVC (%) in the observation group was better than that in the control group (P <0.05). After treatment, PaO2 increased, PaO2 decreased and the positive rate of TGF-β1 decreased (P <0.05). The observation group and control group improved more significantly (P <0.05). Conclusion: Tanreqing injection combined with SiLihua treatment of chronic obstructive pulmonary disease patients with significant effect, can improve lung function and respiratory conditions, reduce the positive rate of TGF-β1, worthy of clinical application.